Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Moodys
Express Scripts
AstraZeneca
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for TD-4208

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for TD-4208?

TD-4208 is an investigational drug.

There have been 13 clinical trials for TD-4208. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Theravance Biopharma R & D, Inc., Theravance Biopharma, and Mylan Inc.

There are thirty-three US patents protecting this investigational drug and one hundred and twenty-two international patents.

Recent Clinical Trials for TD-4208
TitleSponsorPhase
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Subjects With COPDMylan Inc.Phase 3
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Subjects With COPDTheravance BiopharmaPhase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDTheravance Biopharma R & D, Inc.Phase 3

See all TD-4208 clinical trials

Clinical Trial Summary for TD-4208

Top disease conditions for TD-4208
Top clinical trial sponsors for TD-4208

See all TD-4208 clinical trials

US Patents for TD-4208

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TD-4208   Start Trial Crystalline freebase forms of a biphenyl compound THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
TD-4208   Start Trial Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
TD-4208   Start Trial Biphenyl compounds useful as muscarinic receptor antagonists Theravance, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
McKinsey
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.